SCHEMBL6404244

SCHEMBL6404244

Nc1cc(C(=O)Nc2ccccc2C(=O)O)ccc1Oc1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.56
CHEK1 O14757 1/20 0.56
PIM1 P11309 1/20 0.56
MAPK8 P45983 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
KDM4E B2RXH2 1/20 0.54
PYGL P06737 2/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PYGM P11217 1/20 0.53
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 1/20 0.53
HTT P42858 1/20 0.53
RAB9A P51151 1/20 0.53
KCNH2 Q12809 1/20 0.53
PKM P14618 1/20 0.52
CASP3 P42574 1/20 0.52
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401893 0.89 KDM4E (0.57) CHEK1PIM1MAPK8CLK4KDM4E
SCHEMBL6408811 0.85 MEN1 (0.64) DHODHKDM4EPYGLMEN1KMT2A
SCHEMBL8044197 0.82 DHODH (0.79) DHODHCHEK1PIM1MAPK8CLK4
SCHEMBL7129478 0.78 PYGL (0.72) DHODHPYGLPYGMNPC1RAB9A
SCHEMBL6408612 0.78 HCAR2 (0.61) DHODHMEN1KMT2ANPC1RAB9A
SCHEMBL2292834 0.75 CHEK1 (0.65) CHEK1PIM1MAPK8CLK4MEN1
SCHEMBL2025586 0.75 MEN1 (0.72) DHODHCHEK1PIM1MAPK8CLK4
SCHEMBL30466712 0.75 MEN1 (0.72) DHODHCHEK1PIM1MAPK8CLK4
SCHEMBL2330281 0.75 MEN1 (0.69) MEN1KMT2APYGMNPC1RAB9A
SCHEMBL1454287 0.74 DEGS1 (0.53) MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient TEIJIN LIMITED 2005-02-03 US disclosed
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients TEIJIN LIMITED (JP) 2003-11-27 US disclosed
EP-1256341-A1 CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT TEIJIN LIMITED (JP) 2002-11-13 EP disclosed
CN-1048239-C Naphthalene deriv. TEIJIN LTD (JP) 2000-01-12 CN disclosed
CN-1153511-A Naphthalene deriv. TEIJIN LTD (JP) 1997-07-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients HCCS, BCOR, CBR1 DHODH 687/4885CHEK1 830/4885PIM1 4744/4885
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient CA9, HCCS, CA7 DHODH 962/4885CHEK1 866/4885PIM1 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.